ScholarIQanswers from OpenAlex

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway

PaperCitations, authors & open-access status

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway have?

ScholarIQcitation count

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway has 31 citations in the OpenAlex counts ScholarIQ stores.

When was Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway published?

ScholarIQyear

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway has 2021 year in the ScholarIQ index.

What is the open-access status of Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

ScholarIQoa status

Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway has hybrid oa status in the ScholarIQ index.

What is the DOI of Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

ScholarIQdoi

The DOI for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is on the source record.

What is the PMID of Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

ScholarIQpmid

The PMID for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is on the source record.

What is the OpenAlex record for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway?

ScholarIQopenalex

The OpenAlex for Tofacitinib Ameliorates Lipopolysaccharide‐Induced Acute Kidney Injury by Blocking the JAK‐STAT1/STAT3 Signaling Pathway is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial